BCR::ABL1阳性急性淋巴细胞白血病中的微小残留病:在典型ALL与CML样疾病中意义不同
该回顾性分析纳入147例BCR::ABL1阳性急性淋巴细胞白血病(ALL)患儿,采用DNA监测BCR::ABL1基因组断裂点及免疫球蛋白/T细胞受体基因重排。CML样(n=48)与典型ALL(n=99)的5年无事件生存率分别为60%和49%,5年总生存率分别为75%和73%。MRD在典型ALL中预后意义显著(多因素分析EFS p=0.0005),在CML样患者中不显著(p值>0.2)且不适用于治疗调整。
要点
- 典型ALL与CML样患者总体预后相似,但典型ALL复发更多,CML样患者首缓解期死亡更多。
- MRD在典型ALL中对EFS有显著预后价值(多因素分析p=0.0005),在CML样中不显著(p>0.2)。
- 典型ALL中结合初始高白细胞血症可进一步改善风险预测;CML样尚未发现可用于治疗调整的预后特征。
核心结论
- 早期区分典型BCR::ABL1阳性ALL与CML样患者对于在即将开展的方案中实现最佳治疗至关重要。
- 对于典型ALL,推荐酪氨酸激酶抑制剂联合风险导向强度的化疗;对于CML样疾病,迄今未发现适用于治疗调整的相关预后特征。
研究设计与样本
- 回顾性分析147例BCR::ABL1阳性ALL患儿(诊断时间2000年1月至2021年4月),其中133例按EsPhALL方案治疗,14例按其他方案治疗。
- 采用基于DNA的BCR::ABL1基因组断裂点及克隆性免疫球蛋白/T细胞受体基因重排监测MRD。
主要发现
- CML样组(n=48)与典型ALL组(n=99)的5年无事件生存率分别为60%和49%,5年总生存率分别为75%和73%。
- 典型ALL组复发更多,而CML样组首缓解期死亡更多。
- MRD在典型ALL组中对EFS的多因素分析p=0.0005,预后意义显著;在CML样组中p值>0.2,不显著且不适用于治疗调整。
- 在典型ALL组中,结合初始高白细胞血症可进一步改善风险预测。
关键数值与推荐
- 典型ALL组MRD对EFS的多因素分析p=0.0005。
- CML样组MRD对EFS的p值>0.2。
- CML样组5年EFS 60%,5年OS 75%;典型ALL组5年EFS 49%,5年OS 73%。
临床怎么用
- 对于典型ALL,推荐酪氨酸激酶抑制剂联合风险导向强度的化疗。
- 对于CML样疾病,迄今未发现适用于治疗调整的相关预后特征。
- 早期区分典型BCR::ABL1阳性ALL与CML样患者对于在即将开展的方案中实现最佳治疗至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recently, we defined "CML-like" subtype of BCR::ABL1-positive acute lymphoblastic leukemia (ALL), resembling lymphoid blast crisis of chronic myeloid leukemia (CML). Here we retrospectively analyzed prognostic relevance of minimal residual disease (MRD) and other features in 147 children with BCR::ABL1-positive ALL (diagnosed I/2000-IV/2021, treated according to EsPhALL (n = 133) or other (n = 14) protocols), using DNA-based monitoring of BCR::ABL1 genomic breakpoint and clonal immunoglobulin/T-cell receptor gene rearrangements. Although overall prognosis of CML-like (n = 48) and typical ALL (n = 99) was similar (5-year-EFS 60% and 49%, respectively; 5-year-OS 75% and 73%, respectively), typical ALL presented more relapses while CML-like patients more often died in the first remission. Prognostic role of MRD was significant in the typical ALL (p = 0.0005 in multivariate analysis for EFS). In contrast, in CML-like patients MRD was not significant (p values > 0.2) and inapplicable for therapy adjustment. Moreover, in the typical ALL, risk-prediction could be further improved by considering initial hyperleukocytosis. Early distinguishing typical BCR::ABL1-positive ALL and CML-like patients is essential to enable optimal treatment approach in upcoming protocols. For the typical ALL, tyrosine-kinase inhibitors and concurrent chemotherapy with risk-directed intensity should be recommended; in the CML-like disease, no relevant prognostic feature applicable for therapy tailoring was found so far.
引用
- Zuna J, Hovorkova L, Krotka J, et al. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia. 2022. PMID: 35933523. doi:10.1038/s41375-022-01668-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。